<DOC>
	<DOCNO>NCT00509093</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase II trial study well imatinib mesylate work treat patient newly diagnose acute myeloid leukemia receive chemotherapy .</brief_summary>
	<brief_title>Imatinib Mesylate Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether add imatinib mesylate maintenance therapy improve progression-free survival patient c-kit positive acute myeloid leukemia ( AML ) compare historical control . Secondary - To assess feasibility administer imatinib mesylate maintenance therapy completion induction consolidation therapy patient . - To evaluate potential mechanism relapse/resistance c-kit positive AML examine multidrug resistance gene expression AF1q gene expression determine whether level correlate c-kit expression . OUTLINE : This multicenter study . Patients receive oral imatinib mesylate daily 12 month . Bone marrow peripheral blood collect baseline . Laboratory endpoint evaluate flow cytometry ; mutation gene analysis PCR .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>INCLUSION CRITERIA Diagnostic bone marrow aspirate/ biopsy peripheral blood confirm AML . At time diagnosis , patient must ckit ( also know CD117 ) positive AML ( 20 % blast express ckit [ CD117 ] ) . A flow scattergram ( diagnostic AML specimen ) must available calculate ckit MFI . Patients must receive standard induction chemotherapy ADE ( cytarabine , daunorubicin , etoposide ) 7+3 ( 7 day cytarabine continuous infusion 3 day anthracycline ( idarubicin , daunorubicin , mitoxantrone ) . Patients persistent leukemia Day 1028 marrow may receive second course chemotherapy . After completion induction therapy , patient must attain complete remission base blood count recovery ( neutrophil count ≥ 1,000/µL , platelet count ≥ 100,000/µL ) , bone marrow aspirate biopsy ( &lt; 5 % myeloblast ) . For patient &lt; 60 year age , patient must receive least 2 course postremission therapy least intermediate dose ( 400 mg/m2/day ) . *Patients ( 8 ; 21 ) inversion 16 time diagnosis must receive least 2 course high dose cytarabine . For patient &gt; = 60 year age , patient must receive 1 course postremission therapy ( type chemotherapy specify ) . Patients must register study ( maintenance Imatinib mesylate ) within 60 day last dose postremission therapy . A bone marrow aspirate and/or biopsy must do within 3 week registration document CR . Women childbearing potential sexually active male must use effective method contraception . Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient reproductive potential must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug . ECOG Performance Status 02 . Creatinine must ≤ 1.5 x upper limit normal . Total bilirubin must ≤ 2 mg/dl AST ALT must ≤ 2 time upper limit normal . Previous treatmentrelated toxicity must resolve ≤ Grade 1 exclude alopecia . Written , voluntary inform consent . EXCLUSION CRITERIA Acute promyelocytic leukemia . Patients autologous allogeneic bone marrow transplant . History HIV . Pregnant breastfeeding . Serious poorly control medical condition would interfere protocol . At time study entry , medication could significantly interact imatinib mesylate must discontinue . Patients active extramedullary disease eligible . Patient receive investigational agent within 28 day first day study drug dose . Patient &lt; 5 year free another primary malignancy except : primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . Patient Grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) Patient know chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) . Patient previously receive radiotherapy ≥ 25 % bone marrow Patient major surgery within 2 week prior study entry . Patient significant history noncompliance medical regimen inability grant reliable informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
</DOC>